Its key agent, small-interfering RNA (siRNA), can theoretically silence ... and winner of the 1993 Nobel Prize in Physiology or Medicine. Several mRNA-based products are approved.

The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into ...

Eli Lilly and insitro said the deals offers a “new paradigm” for collaborations between major pharmaceutical companies and smaller biotechs.

Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.